# TAK-928

Source: https://onco.cc/drugs/tak-928/  
OnCo record `tak-928` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TAK-928 is an experimental bispecific antibody from Takeda in phase 3 trials for non-small-cell lung cancer, aimed at PD-1 and CD25 (IL-2 receptor alpha).

## Summary

TAK-928 is a bispecific antibody developed by Takeda. Its targets are PD-1 and CD25 (IL-2 receptor alpha) (the sponsor names PD-1 x IL-2 receptor (CD25)). The sponsor states: Described as a first-in-class bispecific monoclonal antibody comprised of an IL-2 mutein fused with a recombinant anti-PD-1 antibody, intended to simultaneously block PD-(L)1 signalling and deliver IL-2 stimulation to tumour-specific CD8+ T cells co-expressing PD-1 and CD25, to reverse T-cell exhaustion. ClinicalTrials.gov describes the intervention as: TAK-928 will be administered by IV infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07217301 (A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer), in non-small-cell lung cancer. The largest, NCT07217301, plans to enrol 600 participants with primary completion expected 2028-11-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: bispecific antibody
- Mechanism: Described as a first-in-class bispecific monoclonal antibody comprised of an IL-2 mutein fused with a recombinant anti-PD-1 antibody, intended to simultaneously block PD-(L)1 signalling and deliver IL-2 stimulation to tumour-specific CD8+ T cells co-expressing PD-1 and CD25, to reverse T-cell exhaustion.

## Sources

- ClinicalTrials.gov: trials of TAK-928: https://clinicaltrials.gov/search?intr=TAK-928

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [CD25 (IL-2 receptor alpha)](https://onco.cc/targets/cd25/), [PD-1](https://onco.cc/targets/pd1/)
- companies: [Takeda](https://onco.cc/companies/takeda/)
- trials: [A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07217301/)

---
JSON: https://onco.cc/api/v1/entities/tak-928.json